Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGSWW) Return on Sales (2020 - 2025)

GeneDx Holdings has reported Return on Sales over the past 6 years, most recently at 0.15% for Q4 2025.

  • Quarterly results put Return on Sales at 0.15% for Q4 2025, down 20.0% from a year ago — trailing twelve months through Dec 2025 was 0.05% (up 12.0% YoY), and the annual figure for FY2025 was 0.05%, up 12.0%.
  • Return on Sales for Q4 2025 was 0.15% at GeneDx Holdings, down from 0.06% in the prior quarter.
  • Over the last five years, Return on Sales for WGSWW hit a ceiling of 0.76% in Q3 2021 and a floor of 5.03% in Q4 2022.
  • Median Return on Sales over the past 5 years was 0.57% (2021), compared with a mean of 0.91%.
  • Biggest five-year swings in Return on Sales: crashed -434bps in 2022 and later skyrocketed 458bps in 2023.
  • GeneDx Holdings' Return on Sales stood at 0.7% in 2021, then crashed by -624bps to 5.03% in 2022, then soared by 91bps to 0.45% in 2023, then soared by 113bps to 0.06% in 2024, then tumbled by -357bps to 0.15% in 2025.
  • The last three reported values for Return on Sales were 0.15% (Q4 2025), 0.06% (Q3 2025), and 0.1% (Q2 2025) per Business Quant data.